FDA’s benefit–Risk assessment is an integrated judgment about the meaningfulness of benefit, the acceptability of risk, and the tolerance of uncertainty. But no matter how well clinical evaluations are designed and implemented, some remaining uncertainty about a drug’s benefits and risks is inevitable at the time of a new drug approval decision because of the inherent limitations of clinical trials.
JOIN SSIT